Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

In the ever-evolving world of wellness and self-care, finding the right supplement can sometimes feel like searching for a ...

AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Welcome to the healthier, happier world of 2030. Heart attacks and strokes are down 20%. A drop in food consumption has left ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 study ...